Bristol-Myers Squibb Company hits a 52-week high on Q2 results, EPS guidance raise, and key drugs’ momentum. Read why BMY stock is a buy.
Bristol-Myers Squibb: Why I’m Still Bullish After Q2
view original post
Bristol-Myers Squibb Company hits a 52-week high on Q2 results, EPS guidance raise, and key drugs’ momentum. Read why BMY stock is a buy.